ARTICLE IN PRESS

Parkinsonism and Related Disorders xxx (2015) 1-4



Contents lists available at ScienceDirect

Parkinsonism and Related Disorders

journal homepage: www.elsevier.com/locate/parkreldis



Short communication

Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study

S. Arora ^{a, b}, V. Venkataraman ^c, A. Zhan ^d, S. Donohue ^d, K.M. Biglan ^e, E.R. Dorsey ^{e, f, *}, M.A. Little ^{a, g}

- ^a Nonlinearity and Complexity Research Group, Aston University, Birmingham, United Kingdom
- ^b Somerville College, University of Oxford, Oxford, United Kingdom
- ^c Duke University School of Medicine, Durham, NC, United States
- ^d Johns Hopkins University, Baltimore, MD, United States
- ^e Department of Neurology, University of Rochester Medical Center, Rochester, NY, United States
- f CHET, University of Rochester Medical Center, Rochester, NY, United States
- ^g Media Lab, Massachusetts Institute of Technology, Boston, MA, United States

ARTICLE INFO

Article history: Received 13 November 2014 Received in revised form 4 February 2015 Accepted 26 February 2015

Keywords: Parkinson's disease Motor assessment Diagnostic test assessment Smartphone

ABSTRACT

Background: Remote, non-invasive and objective tests that can be used to support expert diagnosis for Parkinson's disease (PD) are lacking.

Methods: Participants underwent baseline in-clinic assessments, including the Unified Parkinson's Disease Rating Scale (UPDRS), and were provided smartphones with an Android operating system that contained a smartphone application that assessed voice, posture, gait, finger tapping, and response time. Participants then took the smart phones home to perform the five tasks four times a day for a month. Once a week participants had a remote (telemedicine) visit with a Parkinson disease specialist in which a modified (excluding assessments of rigidity and balance) UPDRS performed. Using statistical analyses of the five tasks recorded using the smartphone from 10 individuals with PD and 10 controls, we sought to: (1) discriminate whether the participant had PD and (2) predict the modified motor portion of the UPDRS.

Results: Twenty participants performed an average of 2.7 tests per day (68.9% adherence) for the study duration (average of 34.4 days) in a home and community setting. The analyses of the five tasks differed between those with Parkinson disease and those without. In discriminating participants with PD from controls, the mean sensitivity was 96.2% (SD 2%) and mean specificity was 96.9% (SD 1.9%). The mean error in predicting the modified motor component of the UPDRS (range 11–34) was 1.26 UPDRS points (SD 0.16).

Conclusion: Measuring PD symptoms via a smartphone is feasible and has potential value as a diagnostic support tool.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Accurate diagnosis of Parkinson's disease (PD) and other neurological disorders is critical for care and research. However, clinical diagnostic accuracy by a neurologist is limited as up to 20% of cases of may be misdiagnosed by clinicians when compared to post mortem pathology [1]. New imaging modalities, such as SPECT

E-mail address: ray.dorsey@chet.rochester.edu (E.R. Dorsey).

http://dx.doi.org/10.1016/j.parkreldis.2015.02.026 1353-8020/© 2015 Elsevier Ltd. All rights reserved. scans, can assist, but their utility is limited by cost, time, and availability.

Previous studies have objectively characterized pathological changes in motor symptoms [2] such as voice production (using a microphone) [3], posture and gait (using accelerometers) [4], tremor (using finger tapping tasks) [5], and cognitive performance (using reaction times) [6] in PD. Smartphones, which are increasingly inexpensive and ubiquitous, have built-in voice recorders, accelerometers, and touch screens, and can potentially be used to objectively measure PD severity symptoms. For continuous objective motor assessment of PD (such as, freezing of gait, balance deficits and falls), the potential of wearable sensors has been discussed recently [7]. Although smartphones are more ubiquitous

Please cite this article in press as: Arora S, et al., Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study, Parkinsonism and Related Disorders (2015), http://dx.doi.org/10.1016/j.parkreldis.2015.02.026

^{*} Corresponding author. University of Rochester Medical Center, 265 Crittenden, Box CU420694, Rochester, NY 14642, United States. Tel.: +1 585 276 6824; fax: +1 585 461 4594.

2

than wearable sensors, their use by individuals in home settings to differentiate those with PD from controls and to evaluate disease severity has not been previously investigated.

2. Methods

2.1. Study design and study participants

Individuals with PD diagnosed clinically by a movement disorder specialist and control participants were recruited from an academic movement disorder clinic (Johns Hopkins) and all participants provided informed consent. The study was reviewed and approved by the Johns Hopkins Institutional Review Board. Control participants were spouses, caregivers, relatives, or colleagues of an individual with PD and did not have any known neurological disorder. All participants were provided identical LG Optimus S smartphones (cost: \$30 each) with Android OS (Google, Inc.) loaded with specialized software developed by the team (M.A.L.) (Supplemental Fig. 1).

The smartphone software prompted participants to perform the following short tests (less than 5 min): (1) (voice test) say the sustained phonation 'aaah' for as long and as steadily as possible; (2) (posture test) stand upright unaided for 30 s; (3) (gait test) walk twenty steps forward, turn around, and return back to the starting position; (4) (finger tapping test) tap the screen alternately keeping a regular rhythm; and (5) (reaction time test) press and hold the on-screen button as soon as it appears and release it as soon as it disappears.

At an in-person baseline visit, participants were given the smartphone, trained how to use the software application, and instructed how to upload phone data via Wi-Fi to a secure database. The participants were asked to conduct the above specified tests four times daily: just before taking their first (morning) dose of levodopa (or in one case, rasagiline), 1 h later, mid-afternoon, and before going to bed. Demographic information, medical history, and a current medication list were also collected in addition to completing the motor portion of the UPDRS [8], and the Parkinson Disease Questionnaire 39 (PDQ-39), a disease-specific quality of life instrument. The specialists also conducted a remote assessment of the modified UPDRS [8] (that excluded assessments of rigidity and balance) via web-based video conferencing once per week for 4 weeks at approximately the same time each week. To map the summary measures to UPDRS, we derived the UPDRS values corresponding to each summary measure using piecewise linear interpolation, going exactly through the actual UPDRS assessments [3].

2.2. Statistical analysis

Voice impairment may be one the earliest indicators of PD [9] and is typically characterized by reduced loudness, breathiness, roughness, monopitch, and exaggerated vocal tremor. We extracted a range of summary measures that quantify roughness, aperiodicity, aeroacoustic noise in voice (due to incomplete vocal fold closure), and placement of the articulators (mouth, teeth, tongue and lips), some of which are known to be affected in PD [3].

For posture and gait, using the three dimensional accelerometry time traces we calculated different summary measures, ranging from basic statistics, such as mean, standard deviation, and median acceleration, to more sophisticated measures, such as the Teager–Kaiser energy operator and detrended fluctuation analysis, that characterize changes in body motion [4].

For finger tapping, we recorded the screen pixel position (*x*, *y* coordinates) and the time of finger touch. Finger tapping tasks have been used to assess arrythmokinesis, which can include hastening, faltering or freezing in the tapping pattern in PD [5]. Using this finger tap data, we developed novel summary measures that quantify the tapping speed, rhythm, inter-tap interval, fatigue, and tremor.

For the reaction time test, we measured the elapsed time between the stimulus (appearance/disappearance of a screen button) and the corresponding response (press/release of the button). This type of reaction time is also referred to as non-cued simple reaction time and is linked with pre-movement central neural processing [6]. Using this reaction time data, we calculated a range of different summary measures such as mean, coefficient of variation, correlation, and fatigue.

Supplementary Tables 1, 2, 3 and 4 provides an exhaustive list of the summary measures extracted using the voice, posture, gait, finger tapping, and reaction time data, respectively, along with a brief description of each.

The study's overall methodological approach is summarized in Fig. 1. Using random forests [10], a powerful statistical machine learning technique that is commonly used to separate generic data into several different classes, we sought to discriminate participants with PD from controls and predict the modified motor UPDRS scores, solely on the basis of the summary measures derived from the smartphone recordings. Statistical analysis of the smartphone data was performed using the Matlab® software (version 2013a).

2.3. Validation

To validate the method, we used a standard 10-fold, randomized cross-validation method with 100 repetitions. This validation method involves repetitive splitting of the dataset into non-overlapping "training" and "validation" sets.

In total, we identified 1772 recordings that were of decent quality for the analysis. The training set (consisting of 90% of randomly selected smartphone recordings, n=1595 recordings) allows the random forest method to find discriminating patterns in the summary measures. The validation set (consisting of the remaining 10% of recordings, n=177 recordings) is used to assess the method's accuracy; effectively, the random forest method is blinded to these data during training. This randomized selection of training and validation sets is repeated 100 times, leading to different accuracy on each repetition. The mean and standard deviation of the accuracy is then computed over all 100 repetitions. The actual and interpolated UPDRS scores were used in the validation. Furthermore, we performed two statistical tests against the null hypothesis that the discrimination results obtained were no better than randomized determinations of whether one has PD.

3. Results

Twenty participants (10 individuals with PD and 10 controls) enrolled and completed the study, and their baseline characteristics are provided in Table 1. The 20 participants performed an average of 2.7 tests per day (68.9% adherence) for the study's duration (average of 34.4 days). Those with PD performed an average 2.6 tests per day, and controls completed 2.8 tests per day.

The summary measures differed between participants with PD and controls. Using random forests, the mean sensitivity was 96.2% (SD 2%) and mean specificity was 96.9% (SD 1.9%) in discriminating participants with PD from controls. These sensitivity and specificity results differed from comparable results obtained from randomized predictions about which participants had PD or were controls (p < 0.001, two-sided Kolmogorov–Smirnov test).

To predict ongoing symptom severity, our final objective was to replicate the clinician's symptom severity assessment as closely as possible, using only the summary measures. The performance of random forest in predicting symptom severity was assessed using the mean absolute error. The average mean absolute error in predicting the modified motor UPDRS (which ranged from 11 to 34, mean 19.6, SD 6.7) was 1.26 UPDRS points (SD 0.16). The average mean absolute error in predicting the modified motor UPDRS for female participants (UPDRS range 14–29, mean 22.1, SD 4.0) was 1.02 UPDRS points (SD 0.2), while for male participants (UPDRS range 11–34, mean 20.3, SD 5.2), the average mean absolute error was 1.29 (SD 0.2). The UPDRS errors were lower than the inter-rater variability of the UPDRS (4–5 points) [11].

4. Discussion

In this pilot study, we demonstrated that consumer-grade smartphones can be used to accurately differentiate individuals with PD from age-matched controls and potentially predict disease severity, which could be used to monitor disease progression. While the results remain to be confirmed in larger scale studies, they open the door for smartphones to be potentially used as diagnostic and disease management support devices.

Future analyses will quantify response to treatment and intraday symptom variation, which are often impractical to perform in most clinical settings. Furthermore, future assessments could passively record accelerometry time traces continuously in the background, an approach which has shown good success in a recent study [2]

Despite this promise, considerable work remains. This study was limited by size (n = 20 participants) and by the range of PD symptom severity (individuals with mild to moderate PD). The characteristics (e.g., age, sex) of the control participants did not match well those of the participants, which will need to be addressed in future studies. Larger-scale assessments of individuals earlier in their disease course compared to individuals with other disorders that cause changes in voice, impairment in cognitive skills, or result in tremor/gait deficits will better assess

S. Arora et al. / Parkinsonism and Related Disorders xxx (2015) 1-4




Fig. 1. Schematic diagram illustrating the procedure for collecting voice recordings (sustained vowel 'aaah'), acceleration time traces during postural sway and gait tests, finger tapping coordinates and the time of touch, and reaction time (onset of stimulus and response), using commercially-available smartphones, along with the major steps involved in the data analysis. Abbreviations: 3D = three dimensional; DFA = detrended fluctuation analysis; PD = Parkinson's disease; SD = standard deviation.

Table 1Baseline characteristics of study participants.

Parkinson's disease participants ($N=10$)	$\begin{array}{c} \text{Control participants} \\ (N=10) \end{array}$
65.1 years (9.8)	57.7 years (14.3)
30%	60%
90%	0%
100%	100%
19.6 (6.7)	NA
18.5 (16.9)	NA
	participants (N = 10) 65.1 years (9.8) 30% 90% 100% 19.6 (6.7)

NA = not applicable; SD = standard deviation.

the discriminatory potential of such smartphone applications. Importantly, this study did not include individuals with other parkinsonian or tremor disorders that may be more difficult to differentiate from PD. This study was also limited by the variability in the home conduct of the tests and the remote assessments of the UPDRS.

Nearly two centuries after the seminal description of PD and five decades after the development of a highly effective, inexpensive therapy, many individuals in the world with PD have not been diagnosed or received treatment. Simple, inexpensive, widely available technologies are needed to facilitate diagnosis and care. As this study demonstrates, smartphones — whose numbers are projected to reach 3 billion by 2017 [12] — may represent an

4

effective tool for detection, assessment, and potentially care, of this increasingly common disorder.

Financial disclosures of all authors for the past year

Dr. Siddharth Arora receives research support from The Michael J. Fox Foundation for Parkinson's Research.

Mr. Vinayak Venkataraman has no relevant financial disclosures.

Mr. Zhang has no relevant financial disclosures.

Mr. Donohue has no relevant financial disclosures.

Dr. Kevin Biglan received compensation for consulting activities from Lundbeck and UCB, research support from the Davis Phinney Foundation, National Institute of Neurological Disorders and Stroke, Michael J. Fox Foundation, National Parkinson Foundation, Patient-Centered Outcomes Research Institute, Huntington Disease Society of America, and Lundbeck.

Dr. Ray Dorsey has received compensation for consulting activities from Amgen, Clintrex, Lundbeck, mc10, Medtronic, and the National Institute of Neurological Disorders and Stroke, research support from Davis Phinney Foundation, Great Lakes Neurotechnologies, Huntington Study Group, Lundbeck, Michael J. Fox Foundation, Patient-Centered Outcomes Research Institute, Prana Biotechnology, Sage Bionetworks, stock options from Grand Rounds, and compensation for expert testimony.

Dr. Max Little receives research support from the Wellcome Trust and The Michael J. Fox Foundation for Parkinson's Research.

Study sponsorship

This study received no external funding.

Acknowledgments

The authors wish to thank Reham Bedawy, for her help in identifying relevant literature for this work, and Ervin Sejdić for providing us the code for a few summary measures used for gait analysis. We also extend our sincere gratitude to all the individuals who participated in this study and made this research possible.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.parkreldis.2015.02.026.

References

- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. I Neurol Neurosurg Psychiatry 1992:55:181–4.
- [2] Brunato M, Battiti R, Pruitt D, Sartori E. Supervised and unsupervised machine learning for the detection, monitoring and management of Parkinson's disease from passive mobile phone data. In: Predicting Parkinson's disease progression with smartphone data, Kaggle Competition. Available from: https:// kaggle2.blob.core.windows.net/prospector-files/1117/958625cf-3514-4e64b0e7-13ebd3cf9791/kaggle.pdf, [accessed 22.10.14].
- [3] Tsanas A, Little MA, McSharry PE, Ramig LO. Nonlinear speech analysis algorithms mapped to a standard metric achieve clinically useful quantification of average Parkinson's disease symptom severity. J R Soc Interface 2011;8: 842–55.
- [4] Sejdić E, Lowry KA, Bellanca J, Redfern MS, Brach JS. A comprehensive assessment of gait accelerometry signals in time, frequency and time-frequency domains. IEEE Trans Neural Syst Rehabil Eng 2014;22:603–12.
- [5] Taylor Tavares AL, Jefferis GS, Koop M, Hill BC, Hastie T, Heit G, et al. Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov Disord 2005;20:1286–98.
- [6] Gauntlett-Gilbert J, Brown VJ. Reaction time deficits and Parkinson's disease. Neurosci Biobehav Rev 1998;22:865–81.
- [7] Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord 2013;28:1628–37.
- [8] Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM. Potential reliability and validity of a modified version of the unified Parkinson's disease rating scale that could be administered remotely. Parkinsonism Relat Disord 2013;19:218–21.
- [9] Harel B, Cannizzaro M, Snyder PJ. Variability in fundamental frequency during speech in prodromal and incipient Parkinson's disease: a longitudinal case study. Brain Cognition 2004;56:24–9.
- [10] Breiman L. Random forests. Mach Learn 2001;45:5-32.
- [11] Post B, Merkus MP, de Bie RMA, de Haan RJ, Speelman JD. Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord 2005;20:1577–84.
- [12] Pramis J. By 2017 there will almost be as many smartphones as literate adults. In: Digital trends. Available from: http://www.digitaltrends.com/mobile/2017-literate-adults-smartphones/?tru=bHNoSD#ixzz2d1dtkRDg, [accessed 22.10.14].